Distinct Cell-specific Roles of NOX2 and MyD88 in Epileptogenesis

Cayo Almeida1, Renan Paschoalino Pongilio1, Marília Inês Móvio1, Guilherme Shigueto Vilar Higa1, Rodrigo Ribeiro Resende2, Jianxiong Jiang3, Erika Reime Kinjo1 and Alexandre Hiroaki Kihara1*

1Laboratório de Neurogenética, Universidade Federal do ABC, São Bernardo do Campo, Brazil, 2Laboratório de Sinalização Celular e Nanobiotecnologia, Departamento de Bioquímica e Imunologia, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil, 3Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, TN, United States

It is well established that temporal lobe epilepsy (TLE) is often related to oxidative stress and neuroinflammation. Both processes subserve alterations observed in epileptogenesis and ultimately involve distinct classes of cells, including astrocytes, microglia, and specific neural subtypes. For this reason, molecules associated with oxidative stress response and neuroinflammation have been proposed as potential targets for therapeutic strategies. However, these molecules can participate in distinct intracellular pathways depending on the cell type. To illustrate this, we reviewed the potential role of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 2 (NOX2) and myeloid differentiation primary response 88 (MyD88) in astrocytes, microglia, and neurons in epileptogenesis. Furthermore, we presented approaches to study genes in different cells, employing single-cell RNA-sequencing (scRNAseq) transcriptomic analyses, transgenic technologies and viral serotypes carrying vectors with specific promoters. We discussed the importance of identifying particular roles of molecules depending on the cell type, endowing more effective therapeutic strategies to treat TLE.

Keywords: epilepsy, neuroinflammatory diseases, temporal lobe, single-cell analysis, cre recombinase, adeno-associated virus, toll-like receptors, transgenic mice

INTRODUCTION

Temporal lobe epilepsy (TLE) is the most prevalent form of the disease, corresponding to ~40% of the cases, of which one-third are refractory to the current pharmacological treatments (Guedes et al., 2006; Organization, W. H, 2019; Falco-Walter, 2020). It is already established that epileptogenesis is an ongoing process even after the first unprovoked seizure, since rearrangements of the neural networks constantly occur (Kinjo et al., 2016; Kinjo et al., 2018; Royero et al., 2020). This is due to stress factors such as free radicals' production and neuroinflammation, and it contributes to the progression of epilepsy (Pitkänen et al., 2015; Jiang et al., 2019; Borowicz-Reutt and Czuczwar, 2020).

Free radicals, e.g., reactive oxygen species (ROS), play a physiological role in processes such as synaptic plasticity (Beckhauser et al., 2016). They also participate in the pathological aspects of TLE and several brain disorders, such as Alzheimer’s and Parkinson’s diseases, impairing neurotransmission and favoring lipid peroxidation of the neural membrane (Puttachary et al., 2015; Borowicz-Reutt and Czuczwar, 2020). Besides the contribution of ROS in epileptogenesis, damage-associated molecular patterns (DAMPs) interact with Toll-like receptors (TLRs) dependent on myeloid differentiation primary response 88 (MyD88) for glial cell activation, promoting the
release of interleukin 1β (IL-1β) and other proinflammatory molecules (Paschon et al., 2016). The following glial activation and the ongoing communication between astrocytes and microglia can be of most importance in deciding the neuroinflammation fate of the tissue in a pathology (Paschon et al., 2016; Kinoshita and Koyama, 2021).

Indeed, genes related to oxidative stress and neuroinflammation play different roles depending on the cell type in epileptogenesis. In this context, we approached the role of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 2 (NOX2), one of the main sources of ROS triggered by prolonged seizures (Shekh-Ahmad et al., 2019), and MyD88 in epileptogenesis. Furthermore, we discussed the employment of single-cell RNA-sequencing (scRNAseq) transcriptomic analyses, transgenic technologies, and viral serotypes carrying vectors with specific promoters to unravel the role of genes related to oxidative stress and neuroinflammation in epilepsy.

**DISTINCT ROLES OF NOX2 IN MICROGLIA AND NEURONS**

Microglial cells are known as the primary immune cells of the brain. As resident myeloid cells in the brain, they scour the environment removing cellular debris and releasing cytokines and free radicals such as ROS (Rettenbeck et al., 2015; Kinoshita and Koyama, 2021). Therefore, microglia plays a dual role in epileptogenesis, from distinct microglial phenotypes in sclerotic regions of the epileptic brain (Luo et al., 2016; Morin-Brureau et al., 2018) to promoting pro- and/or anti-epileptic activity (Kinoshita and Koyama, 2021).

Several studies demonstrated that *status epilepticus* (SE) elevates the level of ROS produced by microglia hours after its induction in animals (Dal-Pizzol et al., 2000; Steven et al., 2006; Ryan et al., 2014). It has also been identified in the hippocampus of patients with refractory epilepsy (Shekh-Ahmad et al., 2019). The time course of ROS level alteration and the early microglial response may be associated with neural injury in the hippocampus following an insult that promotes epileptogenesis (Rettenbeck et al., 2015). Although other isoforms of the NOX family exist, NOX2 is of particular interest given its prominent expression by microglia. NOX2 is one of the main sources of ROS produced and released in epileptogenesis (Mcelroy et al., 2017; Shekh-Ahmad et al., 2019). In microglia, the GTPase Rab27 induces the movement of NOX2 complex to the plasma membrane (Ejlerskov et al., 2012). Nevertheless, in other cell types, Ras GTPase-activating-like protein (IQGAP1) is crucial for NOX2’s movement towards the cell surface (Ikeda et al., 2005). The inhibition of NOX2 or its genetic ablation in mice reduces D-aspartate receptors (NMDAr) and metabotropic glutamatergic receptors of group II (mGluR3) and group III (mGluR4, 6, 7, 8), specifically (Haslund-Vinding et al., 2017). Besides that, DAMPs receptors coupled to G protein, i.e., N-formyl peptide receptors (FPRs) and P2Y receptors (P2YRs), which, upon stimulation, promote phosphorylation via RAC of cytosolic p47phox leading to its conformational change. Alongside p67phox and p40phox, this protein migrates to the membrane. In their interaction with NOX2 and p23phox, electrons are transferred from the substrate NADPH to molecular oxygen, resulting in superoxide production (Vermot et al., 2021). Additionally, hydrogen peroxide (H2O2) is suitable for triggering the phospholipase A2 (PLA2) pathway through signal-regulated kinase (ERK) and IL-1β production, which targets the IL-1β receptor and MyD88 pathway (Figures 1Ai,ii,iii) (Beckhauser et al., 2016).

The localization of NOX2 in the postsynaptic region is convenient for its role in synaptic plasticity (Bedard and Krause, 2007; Brennan et al., 2009). ROS physiologically acts as a second messenger in the nervous system, mostly supporting synaptic long-term potentiation (LTP) (Hidalgo and Arias-Cavieres, 2016) or long-term depression (LTD) (Francis-Oliveira et al., 2018). In the hippocampus, for instance, ROS activates protein kinases that are essential for neural plasticity. Upon stimulation, NMDAr (containing the subunit GluN2B) promotes a calcium inflow into synapses, which leads to the production of ROS via Phosphoinositide 3-Kinase (PI3K)—Protein Kinase C (PKC), H2O2 and neutral nitric oxide synthase (nNOS) (Beckhauser et al., 2016). Once produced, H2O2 can pass through the plasma membrane to interact with pre- and postsynaptic proteins, modulating the synaptic transmission (Quinn and Gauss, 2004). However, it can also induce damage on neuronal DNA, including chromosomal alterations, breaking of the DNA column and, in the absence of catalyt, oxidation of sulphydryl compounds (–SH), leading to cell death in pathological conditions (Figures 1Bi,ii,iii) (Beckhauser et al., 2016).

**DISTINCT ROLES OF MYD88 IN MICROGLIA AND ASTROCYTES**

TLRs 2, 4, and 9 are expressed in astrocytes, while TLRs 1-9 are expressed in microglia. However, in neuroinflammation, the innate immune response mediated by microglia and astrocytes depends largely on TLR2 and TLR4, respectively, and IL-1R in both cell types. Most TLRs are coupled to the MyD88 adapter, the exception being TLR3, which is activated by double-strand DNA triggering the TRIF pathway. It is also important to mention that TLR4 can be activated by lipopolysaccharide to signal both pathways MyD88 and TRIF (Paschon et al., 2016; Fiebich et al., 2018).

These receptors can be activated by DAMPs, such as High Mobility Group Box 1 (HMGB-1), as observed in epilepsy, and beta-amyloid plaques and alpha-synuclein, in Alzheimer’s and Parkinson’s disease, respectively (Bernaux et al., 2020). These DAMPs can interact with TLR receptors located in astrocytes and microglia membranes. TLR activation leads both cells to secrete
Cytokines and inflammatory molecules that activate NADPH, which aids NOX2 and cyclooxygenase 2 (COX2) activation in microglia (Meng and Yao, 2020). The secretion of cytokines promotes autocrine and paracrine signaling, leading astrocytes and microglia activation into a vicious circle (Vezzani et al., 2013; Bernaus et al., 2020).

In the literature, it is regularly reported the expression of correspondent TLRs by astrocytes and microglia, however, the
release of specific cytokines by these cells depends on the stimulus or pathology. For instance, after seizure activity, the microglia of patients with TLE release IL-1β, CXCL8, IL-6 and TNFα (Morin-Brureau et al., 2018). On the other hand, in an LPS-induced Parkinson’s model, the up-regulation of IFN-γ, IL-1β, IL-1R, IL-16, IL-17 levels in microglia have been reported. Therefore, it can be inferred that cytokines’ release by microglia depends on many factors, although using the same intracellular signaling pathway, the NF-κB and NLRP3 inflammasome (Chien et al., 2016). When immunologically stimulated by TNFα or IL-1β, post-mortem or biopsy human astrocytes and cell-line NT2 astrocytes release cytokines IL-1β, TNFα, and IL-13. However, post-mortem or biopsy human astrocytes also produced IL-2, IL-7, TNFB, and IFN-γ (Figures 1i,ii) (Burkert et al., 2012).

Microglia activation by TLRs and MyD88 modulate distinct epileptogenesis features. In this cell type, MyD88 signaling promotes cytokine secretion and induces apoptosis of neighboring cells. Microglia potentializes the immune response by recruiting peripheral immune system cells, increasing the inflammatory environment (Meng and Yao, 2020). TLR2 signalling activates IL-1 Receptor-Associated Kinase 4 (IRAK4) in the MyD88-dependent axis. Once activated, IRAK4 phosphorylates p47phox on several residues to activate NOX2 (Pacquelet et al., 2007). Besides that, microglia disrupts gamma-aminobutyric acid (GABA) signaling and regulates the neural expression of NR1 and NR2b subunits of NMDA receptor. These processes result in high excitability of neurons which, in turn, contributes to epileptogenesis (Vezzani et al., 2013; Liu et al., 2018; Xueying Li et al., 2021).

On the other hand, MyD88 signaling modulates the astroglial tissue-maintenance functions, such as ions and neurotransmitters homeostasis (Li et al., 2020; Vezzani et al., 2013). In neuroinflammation, astroglial activation through the MyD88 pathway creates a harmful environment to the neural tissue, characterized by an astrocytic hypertrophic state, which impairs the blood-brain barrier and neural communication maintenance. (Vezzani et al., 2013; Liu et al., 2018; Xueying Li et al., 2021). Astrocytic activation can occur by MyD88-dependent TLR4 via the extracellular signal-related kinase (ERK) pathway, and promotes excitatory synapse development, resulting in increased seizure susceptibility (Henneberger and Steinhauser, 2016; Shen et al., 2016). In this context, the increased expression of TLR4 in astrocytes, but not in microglia, suggests TLR4’s role in seizure frequency in human epilepsy (Pernhorst et al., 2013).

The crosstalk involving the MyD88 pathway in microglia and astrocytes seems crucial in triggering inflammation in the central nervous system (CNS), given that the absence of microglia in vitro and in vivo leads to a failure of TLR4 activation in astrocytes, consequently reducing the inflammatory response (Barbierato et al., 2013; Liddelow et al., 2017). In epileptogenesis, neuroinflammation contributes to the pathological synaptic plasticity and dendrite growth by activating IL-1R/TLR receptors, transcription factor NF-κB, and cytokines effects (Vezzani et al., 2013; Meng and Yao, 2020).

Therefore, anti-inflammatory therapies and pharmacological drugs that influence the signaling pathway involving TLR4/MyD88/NF-κB/NLRP3/IL-1β, such as baicalin (TLR4 inhibitor) and agmatine (TLR4 down regulator), also reduce the frequency, duration and intensity of seizures (Lun Li et al., 2021; Yang et al., 2021). Furthermore, MyD88 inhibition reduces phosphorylation and expression of NMDAR, modulates proinflammatory microglia, and increases the expression of glutamate receptors in astrocytes (Wang et al., 2017; Liu et al., 2018). These mechanisms support the important role of MyD88 in neuroinflammation associated with epilepsy; in this sense, approaches that directly target MyD88 inhibition demonstrate positive effects in epilepsy. In summary, MyD88 and NOX2 are essential players in epileptogenesis, regulating the neuroinflammatory response in a cell-specific manner, promoting distinct outcomes.

DISCUSSION

Considering that specific cell types have distinct impacts on epilepsy, technologies that allow screening, such as scRNAseq, genetically modified animals, and cell-targeted gene control provide valuable approaches to study epilepsy. New therapeutic strategies are necessary since around one-third of patients with TLE are refractory to clinically available drug treatments.

scRNAseq allows the assessment of the transcriptomic profile of cell-type-specific (Figure 2A). This technique offers insights into the mechanisms involved in epileptogenesis and characterizes the specific contribution of microglia, astrocytes, and neurons in epilepsy (Olsen and Baryawno, 2018; Cid et al., 2021). This approach investigates NOX2 and MyD88 transcriptomic pathways in distinct time points in epileptogenesis in animal models and surgically-extracted nervous tissues. Specific cell types are separately analyzed, and a complete RNA profile is obtained. For instance, RNAseq data of epileptic hippocampus demonstrated the possibility of investigating oxidative stress regulation and inflammatory responses, such as cytokines, cell migration, proliferation, and cell death, which involve TLR2, TLR3, TLR4, TLR7, and C1qα, inflammasome genes, and pyroptosis (Cid et al., 2021).

Besides mapping changes in the transcriptome in cell-type-specific, transgenic animals allow the control of gene expression in a cell-specific manner, such as in the Cre/flox system (Figure 2B). Cre-mice breed with LoxP (floxed) mice results in Cre-LoxP animals. In this condition, Cre enzyme promotes the inversion or deletion of the genes flanked by LoxP sequences, which can be replaced by a reporter gene such as eGFP (Kim et al., 2018). Bringing this approach into the context of specific targets in epilepsy, it is possible to track the downstream effects of MyD88 and NOX2 loss-of-function in cell-type-specific. Indeed, the cell-type-specific gene ablation combined with pharmacological approaches has been demonstrated particularly useful in the determination of the roles of COX2 (Serrano et al., 2011) and prostaglandin receptor EP2 (Nagib et al., 2020; Sluter et al., 2021; Varvel et al., 2021) in animal models of SE.

For example, to test the downstream effects of MyD88 loss in microglia, a transgenic mice model was established to target
microglia chemokine receptors (Cx3cr1) to knockout the MyD88 gene. The authors showed a relationship between neuron maturation and loss of MyD88 in microglia cells, which disrupts the reward-related-memory formation in morphine addiction (Rivera et al., 2019). On the other hand, the Nestin-Cre model directly induces gene modification into neurons and microglia, which showed that the presence of MyD88 in both cell types is not necessary to respond to a nocice stimulus (Braun et al., 2012). Specific neuron modifications are usually achieved with the Synapsin I Cre model (Mcnair et al., 2020), which is capable of modifying differentiated neurons. Regarding astrocytes, although the most used model is the GFAP-Cre, it also promotes changes in non-specific targets; S100b and GLAST are alternatives pointed out to decrease the off-target effects (Guttenplan and Liddelow, 2019; Mcnair et al., 2020). Also, the generation of brain-specific Mn-SOD-deficient mice (brain-Sod22) to study ROS in the hypoxia model (Sasaki et al., 2011) and neurodegenerative diseases (Marecki et al., 2014; Park et al., 2022) demonstrates the application of this technology.

In addition to transgenic animal models, genetic modifications through viral vectors have also opened opportunities for studying TLE (Figure 2C). Amongst these, adeno-associated virus (AAV) stands out given that its variations have distinct tropism for cell-type-specific. Also, AAV vectors have been used for gene therapy applications due to their safety and the ability to infect dividing and non-dividing cells, performing a long-term transgene expression profile (Daya and Berns, 2008). For instance, AAV can be applied to increase CCL2, aiming to rescue the expression of cytokine levels (CCL2, IL-1β), since these cytokines were described as reduced by other therapies (Wu et al., 2019).

AAV allows control of the gene expression by inserting the gene of interest (GOI), or a sequence that generates a short hairpin RNA (shRNA) to target the GOI, in the host DNA. This
modification promotes overexpression or knockdown of the GOI in the host cell (Daya and Berns, 2008). Several serotypes have been identified in AAV, increasing the probability of transfection of cell-type-specific. For CNS, serotype 2 (AAV2) is the most adopted virus despite the variability of transfection efficiency regarding the cell type, which is overcome by using pseudotyping AAVs by recombining new capsids from different serotypes (Fakhiri and Grimm, 2021). Neurons and astrocytes are efficiently transfected by AAV, both in vivo and in vitro. Also, vectors have been tested for transfection efficiency and transgene expression, demonstrating that AAV5 (Griffin et al., 2019) and AAV8 (Aschauer et al., 2013) are potent viral vectors to transfect astrocytes, while AAV2/1 (Hammond et al., 2017) and AAV9 (Aschauer et al., 2013) are best suitable for neurons. Microglia are the most refractile cells in the nervous system to AAV transfection, but several improvements have been made. For instance, a modified rAAV6 combined with specific microglial promoters succeeded in transfecting these cells in vitro and in vivo (Rosario et al., 2016; Su et al., 2016). Therefore, by employing specific serotypes, it is possible to overexpress or knockdown the expression of genes implied in the epileptogenesis process, such as NOX2 and MyD88, in cell-type-specific.

Cell-type-specific approaches grant benefits in research and scientific study development. However, the lack of reproducibility and technical difficulties might be the reasons for possibly delivering biased results, such as in the RNA-seq case (Whitley et al., 2016). In the Cre/lox system, specific tissue promoters can be expressed in undesired tissues and at uncommon times (Sauer, 1998). At last, their use for in-human treatment may not be indicated, such as in the case of AAV therapies, which hold genotoxicity potential (Colella et al., 2018). Epilepsy has already demonstrated to be multifactorial, therefore a single treatment based on monotherapy will probably not be efficient, especially in refractory TLE (Vezzani et al., 2013; Organization, W. H, 2019; Falco-Walter, 2020).

In summary, cell-type-specific approaches should be applied to investigate mechanisms related to brain disorders. This strategy promotes a better understanding of genes involved in epileptogenesis, bringing new insights into treatments and therapies for TLE (Couvillion et al., 2009).

**AUTHOR CONTRIBUTIONS**

Wrote the first draft of the manuscript: CA, RP, MM, GH. Revised the manuscript: RR, JJ, EK, AK. Conceived the study: AK.

**FUNDING**

AK is grateful for grants from FAPESP (#2019/17892-8, #2020/11667-0), CNPq (#431000/2016-6 and #312047/2017-7), and CAPES (financial code 001). JJ is grateful for NIH/NINDS grants: R01NS100947, and R61NS124923. The funders had no role in study design, data collection and analysis, decision to publish, or manuscript preparation.

**REFERENCES**

Aschauer, D. F., Kreuz, S., and Rumpel, S. (2013). Analysis of Transduction Efficiency, Tropism and Axonal Transport of AAV Serotypes 1, 2, 5, 6, 8 and 9 in the Mouse Brain. PLoS One 8, e76310. doi:10.1371/journal.pone.0076310

Barbierato, M., Facchi, L., Argentini, C., Marinelli, C., Skaper, S., and Giusti, P. (2013). Astrocyte-microglia Cooperation in the Expression of a Pro-inflammatory Phenotype. *Oxid Med. & Cell. Longevity* 12, 608–618. doi:10.2174/1871527311312990064

Beckhauser, T. F., Francis-Oliveira, J., and De Pasquale, R. (2016). Reactive Oxygen Species: Physiological and Pathophysiological Effects on Synaptic Plasticity. *J. Exp. Neurosci.* 10, 23–48. doi:10.4137/JEN.S39887

Bedard, K., and Krause, K.-H. (2007). The NOX Family of ROS-Generating NADPH Oxidases: Physiology and Pathophysiology. *Physiol. Rev.* 87, 245–313. doi:10.1152/physrev.00044.2005

Bernaus, A., Blanco, S., and Sevilla, A. (2020). Glia Crosstalk in Neuroinflammatory Diseases. *Front. Cell. Neurosci.* 14, 209. doi:10.3389/fncel.2020.00209

Borowicz-Reutt, K. K., and Czuczwar, S. J. (2020). Role of Oxidative Stress in Epileptogenesis and Potential Implications for Therapy. *Pharmacol. Rep.* 72, 1218–1226. doi:10.1016/j.pharep.2020.02.00143-w

Braun, T. P., Grossberg, A. J., Velea-Rotse, B. O., Maxson, J. E., Szumowski, M., Barnes, A. P., et al. (2012). Expression of Myoid Differentiation Factor 88 in Neurons Is Not Requisite for the Induction of Sickness Behavior by Interleukin-1β. *J. Neuroinflammation* 9, 229. doi:10.1186/1742-2094-9-229

Brennan, A. M., Won Suh, S., Joon Won, S., Narasimhan, P., Kauppinen, T. M., Lee, H., et al. (2009). NADPH Oxidase Is the Primary Source of Superoxide Induced by NMDA Receptor Activation. *Nat. Neurosci.* 12, 857–863. doi:10.1038/nn.2334

Burkert, K., Moodley, K., Angel, C. E., Brooks, A., and Graham, E. S. (2012). Detailed Analysis of Inflammatory and Neuronal CA2+-dependent Cytokine Secretion from Human NT2 Astrocytes Using Multiplex Bead Array. *Neurochem. Int.* 60, 573–580. doi:10.1016/j.neuint.2011.09.002

Chandran, R., Kim, T., Mehta, S. L., Udhö, E., Chanana, V., Cengiz, P., et al. (2018). A Combination Antioxidant Therapy to Inhibit NOX2 and Activate Nr2 Decreases Secondary Brain Damage and Improves Functional Recovery after Traumatic Brain Injury. *J. Cereb. Blood Flow Metab.* 38, 1818–1827. doi:10.1177/0271678x17738701

Chih, V., Le Charpentier, T., Lebon, S., Oré, M.-V., Celador, I. L., Josserand, J., et al. (2013). Characterization of Phenotype Markers and Neutonotoxic Potential of Polorised Primary Microglia *In Vitro*, *Brain, Behav. Immun.* 32, 70–85. doi:10.1016/j.bbi.2013.02.005

Chien, C.-H., Lee, M.-J., Liu, H.-C., Liu, H.-H., and Fu, W.-M. (2016). Microglia-Derived Cytokines/Chemokines Are Involved in the Enhancement of LPS-Induced Loss of Nigrostriatal Dopaminergic Neurons in DJ-1 Knockout Mice. *PLoS One* 11, e0151569. doi:10.1371/journal.pone.0151569

Cid, E., Marquez-Galera, A., Valero, M., Gal, B., Medeiros, D. C., Navarron, C. M., et al. (2021). Sublayer- and Cell-type-specific Neuronegene therapeutic Transcriptional Trajectories in Hippocampal Sclerosis. *Cell Rep.* 35, 109229. doi:10.1016/j.celrep.2021.109229

Colella, P., Ronzitti, G., and Mingozzi, F. (2018). Emerging Issues in AAV-Mediated *In Vivo Gene Therapy*. *Mol. Ther. - Methods & Clin. Dev.* 8, 87–104. doi:10.1016/j.omtm.2017.11.007

Couvillion, M. T., Lee, S. R., Hogstad, B., Malone, C. D., Tonkin, L. A., Sachidanandam, R., et al. (2009). Sequence, Biogenesis, and Function of Diverse Small RNA Classes Bound to the Piwi Family Proteins of Tetrahymena Thermophila. *Genes. Dev.* 23, 2016–2032. doi:10.1101/gad.1821209

Dal-Pizzato, F., Klamt, F., Vianna, M. M. R., Schröder, N., Quevedo, J., Benfato, M. S., et al. (2000). Lipid Peroxidation in hippocampus Early and Late after Status...
Epileptogenesis: Oxidative Stress and Neuroinflammation

Epileptogenic Induced by Pilocarpine or Kainic Acid in Wistar Rats. Neurosci. Lett. 291, 179–182. doi:10.1016/s0304-3904(00)01409-9

Daya, S., and Berns, K. I. (2008). Gene Therapy Using Adeno-Associated Virus Vectors. Clin. Microbiol. Rev. 21, 583–593. doi:10.1128/cmr.00088-08

Fijkers, P., Christensen, D. P., Beyer, D., Burritt, J. B., Packel, M.-H., Gorlach, A., et al. (2012). NADPH Oxidase Is Internalized by Clathrin-Coated Pits and Localizes to a Rab27A/B GTPase-Regulated Secretory Compartment in Activated Macrophages. J. Biol. Chem. 287, 4835–4852. doi:10.1074/jbc.m111.293696

Fakhri, J., and Grimm, D. (2021). Best of Most Possible Worlds: Hybrid Gene Therapy Vectors Based on Parvoorviruses and Heterologous Viruses. Mol. Ther. 29, 3359–3382. doi:10.1038/syjnl.2021.004.005

Falco-Walter, J. (2020). Epilepsy-Definition, Classification, Pathophysiology, and Epidemiology. Semin. Neurol. 40, 617–623. doi:10.1055/s-0040-1718719

Fiebig, B. L., Batista, C. A. R., Saliba, S. W., Youssif, N. M., and De Oliveira, A. C. P. (2018). Role of Microglia TLRs in Neurodegeneration. Front. Cell. Neurosci. 12, 329. doi:10.3389/fncel.2018.00329

Francis-Oliveira, J., Vilar Higa, G. S., Mendonça Munhoz Dati, L., Carvalho Shieh, F. A., Galvis-Alonso, O. Y., and Leite, J. P. (2006). Plasticidade neuronal – Metabotropic Glutamate Receptors Contributes to Glutamate Neurotoxicity through the Production of Reactive Oxygen Species and Calpain Activation. J. Neuropathol. Exp. Neurol. 65, 1020. doi:10.1097/nen.159.5625.1035. doi:10.1523/jneurosci.2617-17.2018

Guttenplan, K. A., and Liddelow, S. A. (2019). Astrocytes and Microglia: Models for Adjunctive Treatment of Status Epilepticus. Pharmacol. Ther. 210, doi:10.1016/j.pharmthera.2020.107504

Hampson, S. L., Leek, A. N., Richman, E. H., and Tjalkens, R. B. (2017). Cellular Metabotropic Glutamate Receptors Contributes to Glutamate Neurotoxicity in Vivo through the Production of Reactive Oxygen Species and Calpain Activation. J. Neurophysiol. Exp. Neurol. 70, 1020–1035. doi:10.1079/ten.0b013e31828358e4

Hammond, S. L., Leek, A. N., Richman, E. H., and Tjalkens, R. B. (2017). Cellular Selectivity of AAV Serotypes for Gene Delivery in Neurons and Astrocytes by Neonatal Intracerebroventricular Injection. PLoS One 12, e0188830. doi:10.1371/journal.pone.0188830

Hennepencher, C., and Steinhäuser, C. (2016). Astrocytic TLR4 at the Crossroads of Inflammation and Seizure Susceptibility. J. Cell Biol. 215, 607–609. doi:10.1083/jcb.201611078

Hidalgo, C., and Arias-Cavières, A. (2016). Calcium, Reactive Oxygen Species, and Synaptic Plasticity. Physiology 31, 201–215. doi:10.1084/physiol00038.2015

Ikeda, S., Yamaoka-Tojo, M., Håkenski, L., Patrushev, N. A., Anwar, G. M., Quinn, M. T., et al. (2005). Iqgapi1 Regulates Reactive Oxygen Species-dependent Endothelial Cell Migration through Interacting with Nox2. Arterioscler. Thromb. Vasc. Biol. 25, 2295–2300. doi:10.1161/01.ATV.01.2008742.55437. af

Jiang, J., Yu, Y., Kinjo, E. R., Du, Y., Nguyen, H. P., and Dingledine, R. (2019). Suppressing Pro-inflammatory Prolactin Sigaling Attenuates Inflammatory-Associated Neural Network Changes and High-Order Statistics. Mol. Neurobiol. 55, 3990–3998. doi:10.1007/s12035-017-0823-2

Kinoshita, S., and Koyama, R. (2021). Pro- and Anti-epileptic Roles of Microglia. Neuro Regen. Res. 16, 1369–1371. doi:10.4103/1673-5374.4309976

Liddle, R. A., Rettenbeck, M. L., Rüden, E.-L. V., Bienas, S., Carlson, R., Stein, V. M., Tipold, A., et al. (2018). Microglial ROS Production in an Electrical Rat Post-status

Frontiers in Cell and Developmental Biology | www.frontiersin.org

7

July 2022 | Volume 10 | Article 926776

Ameida et al.
